BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16595709)

  • 1. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.
    Girard H; Villeneuve L; Court MH; Fortier LC; Caron P; Hao Q; von Moltke LL; Greenblatt DJ; Guillemette C
    Drug Metab Dispos; 2006 Jul; 34(7):1220-8. PubMed ID: 16595709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
    Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
    Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients.
    Sandanaraj E; Jada SR; Shu X; Lim R; Lee SC; Zhou Q; Zhou S; Goh BC; Chowbay B
    Pharmacogenomics J; 2008 Jun; 8(3):174-85. PubMed ID: 17700594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
    Ramírez J; Liu W; Mirkov S; Desai AA; Chen P; Das S; Innocenti F; Ratain MJ
    Drug Metab Dispos; 2007 Dec; 35(12):2149-53. PubMed ID: 17761781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association analysis of UGT1A genotype and haplotype with SN-38 glucuronidation in human livers.
    Wang H; Bian T; Jin T; Chen Y; Lin A; Chen C
    Pharmacogenomics; 2014 Apr; 15(6):785-98. PubMed ID: 24897286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.
    Hanioka N; Ozawa S; Jinno H; Ando M; Saito Y; Sawada J
    Xenobiotica; 2001 Oct; 31(10):687-99. PubMed ID: 11695848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38).
    Gagné JF; Montminy V; Belanger P; Journault K; Gaucher G; Guillemette C
    Mol Pharmacol; 2002 Sep; 62(3):608-17. PubMed ID: 12181437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Cecchin E; Innocenti F; D'Andrea M; Corona G; De Mattia E; Biason P; Buonadonna A; Toffoli G
    J Clin Oncol; 2009 May; 27(15):2457-65. PubMed ID: 19364970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Paoluzzi L; Singh AS; Price DK; Danesi R; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
    J Clin Pharmacol; 2004 Aug; 44(8):854-60. PubMed ID: 15286088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
    Jinno H; Tanaka-Kagawa T; Hanioka N; Saeki M; Ishida S; Nishimura T; Ando M; Saito Y; Ozawa S; Sawada J
    Drug Metab Dispos; 2003 Jan; 31(1):108-13. PubMed ID: 12485959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs.
    Villeneuve L; Girard H; Fortier LC; Gagné JF; Guillemette C
    J Pharmacol Exp Ther; 2003 Oct; 307(1):117-28. PubMed ID: 12944498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.
    Yoder Graber AL; Ramírez J; Innocenti F; Ratain MJ
    Pharmacogenet Genomics; 2007 Aug; 17(8):619-27. PubMed ID: 17622938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
    Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
    Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
    Jinno H; Saeki M; Saito Y; Tanaka-Kagawa T; Hanioka N; Sai K; Kaniwa N; Ando M; Shirao K; Minami H; Ohtsu A; Yoshida T; Saijo N; Ozawa S; Sawada J
    J Pharmacol Exp Ther; 2003 Aug; 306(2):688-93. PubMed ID: 12730278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.
    Innocenti F; Liu W; Chen P; Desai AA; Das S; Ratain MJ
    Pharmacogenet Genomics; 2005 May; 15(5):295-301. PubMed ID: 15864130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
    Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
    Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer.
    Fujita K; Ando Y; Nagashima F; Yamamoto W; Eodo H; Araki K; Kodama K; Miya T; Narabayashi M; Sasaki Y
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):515-22. PubMed ID: 17406868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
    Sai K; Saeki M; Saito Y; Ozawa S; Katori N; Jinno H; Hasegawa R; Kaniwa N; Sawada J; Komamura K; Ueno K; Kamakura S; Kitakaze M; Kitamura Y; Kamatani N; Minami H; Ohtsu A; Shirao K; Yoshida T; Saijo N
    Clin Pharmacol Ther; 2004 Jun; 75(6):501-15. PubMed ID: 15179405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups.
    Innocenti F; Grimsley C; Das S; Ramírez J; Cheng C; Kuttab-Boulos H; Ratain MJ; Di Rienzo A
    Pharmacogenetics; 2002 Dec; 12(9):725-33. PubMed ID: 12464801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights into SN-38 Glucuronidation: Evidence for the Important Role of UDP Glucuronosyltransferase 1A9.
    Xiao L; Zhu L; Li W; Li C; Cao Y; Ge G; Sun X
    Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):424-428. PubMed ID: 29076612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.